No quarterly revenue total was found in EDESA BIOTECH, INC.'s SEC filings.
Edesa Biotech, Inc. (EDSA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-5.41M
-209.1% vs year-ago quarter
Operating cash flow
$-3.08M
-81.3% vs year-ago quarter
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
9.64M
+37.0% vs year-ago quarter
Net cash
$10.80M
Q4 FY2025
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EDSA (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- British Columbia, Canada
- Headquarters
- Toronto
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1540159
- Former names
- Stellar Biotechnologies, Inc. (until May 30, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Jun 30, 2026 |
Q2 FY2026 Mar 31, 2026 |
Q1 FY2026 Dec 31, 2025 |
Q4 FY2025 Sep 30, 2025 |
Q3 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$5.5M | -$4.3M | -$2.3M | -$2.5M | -$1.9M |
| Net income | -$5.4M | -$4.2M | -$2.2M | -$2.2M | -$1.7M |
| Operating cash flow | -$3.1M | -$2.0M | -$2.1M | -$1.7M | -$1.7M |
| Total assets | $12.7M | $12.4M | $14.7M | $13.5M | $14.8M |
| Stockholders' equity | $8.8M | $10.2M | $14.0M | $12.5M | $14.1M |
| Cash and investments | $10.3M | $10.0M | $12.1M | $10.8M | $12.4M |
| Total debt | — | — | — | $0 | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Other events
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Aug 20, 2026 | Aug 19, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jun 11, 2026 | Jun 10, 2026 |
All 751 Edesa Biotech, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.